225 related articles for article (PubMed ID: 30414437)
1. Comparison of serum human epididymis protein 4 and CA125 on endometrial cancer detection: A meta-analysis.
Li J; Wang X; Qu W; Wang J; Jiang SW
Clin Chim Acta; 2019 Jan; 488():215-220. PubMed ID: 30414437
[TBL] [Abstract][Full Text] [Related]
2. Serum Human Epididymis Protein 4 Combined with Carbohydrate Antigen 125 for Endometrial Carcinoma Diagnosis: A Meta-Analysis and Systematic Review.
Huang GQ; Xi YY; Zhang CJ; Jiang X
Genet Test Mol Biomarkers; 2019 Aug; 23(8):580-588. PubMed ID: 31373853
[No Abstract] [Full Text] [Related]
3. Serum human epididymis protein 4 vs. carbohydrate antigen 125 and their combination for endometrial cancer diagnosis: a meta-analysis.
Chen Y; Ren YL; Li N; Yi XF; Wang HY
Eur Rev Med Pharmacol Sci; 2016 May; 20(10):1974-85. PubMed ID: 27249595
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of serum human epididymis protein 4, carbohydrate antigen 125 and their combination in endometrial cancer: A meta-analysis.
Wu Q; Bai SN; Song LY; Wu WF; Han LN
Medicine (Baltimore); 2023 Aug; 102(33):e34737. PubMed ID: 37603503
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Serum Human Epididymis Protein 4 and Carbohydrate Antigen 125 as Markers in Endometrial Cancer: A Meta-Analysis.
Hu L; Du S; Guo W; Chen D; Li Y
Int J Gynecol Cancer; 2016 Feb; 26(2):331-40. PubMed ID: 26807564
[TBL] [Abstract][Full Text] [Related]
7. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.
Li F; Tie R; Chang K; Wang F; Deng S; Lu W; Yu L; Chen M
BMC Cancer; 2012 Jun; 12():258. PubMed ID: 22712526
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of the diagnostic accuracy of HE4 for endometrial carcinoma.
Liu J; Han L; Sun Q; Li Y; Niyazi M
Eur J Obstet Gynecol Reprod Biol; 2020 Sep; 252():404-411. PubMed ID: 32711295
[TBL] [Abstract][Full Text] [Related]
9. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study.
Angioli R; Plotti F; Capriglione S; Montera R; Damiani P; Ricciardi R; Aloisi A; Luvero D; Cafà EV; Dugo N; Angelucci M; Benedetti-Panici P
Tumour Biol; 2013 Feb; 34(1):571-6. PubMed ID: 23179397
[TBL] [Abstract][Full Text] [Related]
10. Serum HE4 and CA125 combined to predict and monitor recurrence of type II endometrial carcinoma.
Quan Q; Liao Q; Yin W; Zhou S; Gong S; Mu X
Sci Rep; 2021 Nov; 11(1):21694. PubMed ID: 34737393
[TBL] [Abstract][Full Text] [Related]
11. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.
Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM
Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214
[TBL] [Abstract][Full Text] [Related]
12. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer.
Ortiz-Muñoz B; Aznar-Oroval E; García García A; Covisa Peris A; Perez Ballestero P; Sanchez Yepes M; Garcia Lozano T; Illueca Ballester C; García Garcia E
Tumour Biol; 2014 Jul; 35(7):7249-58. PubMed ID: 24771264
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.
Fujiwara H; Suzuki M; Takeshima N; Takizawa K; Kimura E; Nakanishi T; Yamada K; Takano H; Sasaki H; Koyama K; Ochiai K
Tumour Biol; 2015 Feb; 36(2):1045-53. PubMed ID: 25326813
[TBL] [Abstract][Full Text] [Related]
14. The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis.
Li Y; Wang ZC; Luo L; Mu CY; Xu J; Feng Q; Li SB; Gu B; Ma P; Lan T
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):604-610. PubMed ID: 32016961
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
Ahmed AA; Abdou AM
Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
[TBL] [Abstract][Full Text] [Related]
16. HE4 combined with CA125: favorable screening tool for ovarian cancer.
Ghasemi N; Ghobadzadeh S; Zahraei M; Mohammadpour H; Bahrami S; Ganje MB; Rajabi S
Med Oncol; 2014 Jan; 31(1):808. PubMed ID: 24323399
[TBL] [Abstract][Full Text] [Related]
17. Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders.
Zhang Y; Qiao C; Li L; Zhao X; Li Y
Afr Health Sci; 2014 Dec; 14(4):913-8. PubMed ID: 25834501
[TBL] [Abstract][Full Text] [Related]
18. Comparison of HE4, CA125, and ROMA Diagnostic Accuracy: A Prospective and Multicenter Study for Chinese Women With Epithelial Ovarian Cancer.
Zhang P; Wang C; Cheng L; Zhang P; Guo L; Liu W; Zhang Z; Huang Y; Ou Q; Wen X; Tian Y
Medicine (Baltimore); 2015 Dec; 94(52):e2402. PubMed ID: 26717395
[TBL] [Abstract][Full Text] [Related]
19. HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status.
O'Toole SA; Huang Y; Norris L; Power Foley M; Shireen R; McDonald S; Kamran W; Ibrahim N; Ward M; Thompson C; Murphy C; D'Arcy T; Farah N; Heron E; O'Leary JJ; Abu Saadeh F; Gleeson N
Gynecol Oncol; 2021 Feb; 160(2):514-519. PubMed ID: 33213897
[TBL] [Abstract][Full Text] [Related]
20. Human epididymis protein 4 in endometrial cancer: A meta-analysis.
Li LM; Zhu YX; Zhong Y; Su T; Fan XM; Xi Q; Li MY; Fu J; Tan H; Liu S
Clin Chim Acta; 2018 Jul; 482():215-223. PubMed ID: 29630870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
